The independent monitoring board overseeing a trial of four investigational agents for the treatment of patients with Ebola virus disease has recommended the early termination of the trial because of favourable results with two of the four candidates.
The Pamoja Tulinde Maisha (PALM [together save lives]) study recruited 681 patients at four Ebola Treatment Centers (ETCs) in the Democratic Republic of the Congo (DRC) between November 20, 2018 and August 9, 2019. Participants were randomised to receive one of four investigational agents namely; ZMapp, remdesivir, mAb114 and REGN-EB3.
Preliminary results in 499 study participants have now indicated that individuals receiving REGN-EB3 or mAb114 had a greater chance of survival compared to those participants in the other two arms.
The board overseeing the trial has recommended that the study be stopped and all future patients be randomised to receive either REGN-EB3 or mAb114 in what is being considered an extension phase of the study.
As of 11 August, 2,831 cases of Ebola have been reported in the DRC including 2,737 confirmed and 94 probable cases. A total of 1,892 deaths have been reported.